UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 17,899 Shares of West Pharmaceutical Services, Inc. $WST

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 2.0% in the second quarter, HoldingsChannel.com reports. The fund owned 884,865 shares of the medical instruments supplier’s stock after selling 17,899 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in West Pharmaceutical Services were worth $317,667,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Bank of Nova Scotia lifted its holdings in shares of West Pharmaceutical Services by 337.8% during the 1st quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock worth $16,373,000 after acquiring an additional 50,402 shares during the period. Hsbc Holdings PLC lifted its stake in West Pharmaceutical Services by 23.3% during the fourth quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock worth $40,425,000 after purchasing an additional 27,745 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of West Pharmaceutical Services by 100.2% in the 1st quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier’s stock valued at $52,549,000 after purchasing an additional 104,924 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in shares of West Pharmaceutical Services by 6.7% in the 1st quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock valued at $32,826,000 after purchasing an additional 8,179 shares during the last quarter. Finally, Ilmarinen Mutual Pension Insurance Co acquired a new position in shares of West Pharmaceutical Services during the 4th quarter worth $3,027,000. 93.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have commented on WST shares. KeyCorp boosted their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research note on Thursday, July 2nd. Evercore restated an “outperform” rating and issued a $425.00 price target on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Wolfe Research started coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They set an “outperform” rating and a $375.00 price target on the stock. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They issued an “outperform” rating and a $447.00 price objective for the company. Finally, Stephens restated an “overweight” rating and issued a $360.00 target price on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Trading Up 1.2%

NYSE WST opened at $341.43 on Tuesday. The stock has a market capitalization of $24.03 billion, a P/E ratio of 43.72, a P/E/G ratio of 2.36 and a beta of 1.15. The business has a 50 day simple moving average of $350.79 and a 200 day simple moving average of $304.68. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. West Pharmaceutical Services, Inc. has a one year low of $223.83 and a one year high of $386.00.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. During the same period last year, the business earned $1.84 EPS. West Pharmaceutical Services’s quarterly revenue was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Research analysts expect that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.27%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.